NFKB1 and B-cell chronic lymphocytic leukemia: In a similar way, carfilzomib is also reported to activate NF-κB through an atypical or calpain-mediated NF-κB pathway in CLL cells which is IKK-independent and directly promotes p50/p65 nuclear translocation [15].